Premium
The nitroblue tetrazolium (NBT) dye test in determining fever source in lymphoma
Author(s) -
Anderson Tom,
Schein Philip S.,
Jencks Judith A.,
Binder Richard A.
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197409)34:3<705::aid-cncr2820340329>3.0.co;2-l
Subject(s) - medicine , lymphoma , nitroblue tetrazolium , procarbazine , prednisone , population , immunology , malignancy , phagocytosis , pathology , chemotherapy , vincristine , cyclophosphamide , environmental health
A prospective evaluation of the nitroblue tetrazolium (NBT) dye reduction reaction revealed that the response of neutrophils from 76 lymphoma patients was comparable to a control population of 44 patients without underlying malignancy. The NBT test proved to be a useful adjunct in distinguishing fever as a systemic manifestation of underlying lymphoma from that secondary to bacterial infection. In contrast to lymphoma patients with „B” fever, bacterially‐infected lymphoma patients had elevated resting NBT scores comparable to a control population with bacterial infections. Lymphoma chemotherapy, including prednisone, did not inhibit neutrophilic response to infection or latex particle phagocytosis, but Procarbazine may have produced a false positive response in some patients. It is essential to perform a simultaneous latex particle stimulation control to rule out an acquired intracellular defect that would otherwise be interpreted as a false negative response.